A meta-analysis of red yeast rice: An effective and relatively safe alternative approach for dyslipidemia

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Li, Yinhua ^a   Jiang, Long ^a   Jia, Zhangrong ^a   Xin, Wei ^a   Yang, Shiwei ^a   Yang, Qiu ^a   Wang, Luya ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTIN; CREATINE KINASE; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; TRIACYLGLYCEROL; BIOLOGICAL PRODUCT; LIPID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIET RESTRICTION; DISEASE SEVERITY; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MUSCLE DISEASE; NEPHROTOXICITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; ALTERNATIVE MEDICINE; BLOOD; DYSLIPIDEMIAS; LIVER FUNCTION TEST; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

BIOLOGICAL PRODUCTS; COMPLEMENTARY THERAPIES; DYSLIPIDEMIAS; HUMANS; LIPIDS; LIVER FUNCTION TESTS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84902504375     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098611     Document Type: Article

References (40)

1. World Health Organization (2010). Global status report on noncommunicable disaeses 2010. Available: http://www.who.int/nmh/publications/ncd-report2010/ en/. Accessed on April 2011.
2. Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, et al. (2011) National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of healthexamination surveys and epidemiological studies with 321 country-years and 3?0 million participants. Lancet 377: 578-586.
3. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, et al. (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysisof individual data from 27 randomised trials. Lancet 380: 581-590.
4. Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, et al. (2011) AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and otherAtherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and AmericanCollege of Cardiology Foundation. Circulation 124: 2458-2473.
5. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, et al. (2013) Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 1:CD004816.
6. Gotto AM Jr (2006) Statins, cardiovascular disease, and drug safety. Am J Cardiol 97: 3C-5C.
7. Armitage J (2007) The safety of statins in clinical practice. Lancet 370: 1781-1790.
8. Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, et al. (2011) Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol 27: 635-662.
9. Erdogrul O, Azirak S. (2005) A review on the red yeast rice (Monascus purpureus). KSU Journal of Science and Engineering 8: 10-15.
10. Yang CW, Mousa SA (2012) The effect of red yeast rice (Monascus purpureus) in dyslipidemia and other disorders. Complement Ther Med 20: 466-474.
11. Ross SM (2012) Red yeast rice: efficacy and tolerability of Monascus purpureus yeast, for treatment of hyperlipidemia in patientswith statin-associated myalgias. Holist Nurs Pract 26: 173-175.
12. Venero CV, Venero JV, Wortham DC, Thompson PD (2010) Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol 105: 664-666.
13. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, et al. (2006) Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomizedcontrolled trials. Chin Med 1: 4.
14. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of internal medicine 151: 264-269.
15. Higgins JPT, Green S (editors) (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Available at: http:// www.cochranehandbook.org. Accessed on March 2011.
16. Ogier N, Amiot MJ, Georgé S, Maillot M, Mallmann C, et al. (2013) LDL-cholesterol-lowering effect of a dietary supplement with plant extracts in subjects with moderatehypercholesterolemia. Eur J Nutr 52: 547-557.
17. Barrat E, Zaïr Y, Ogier N, Housez B, Vergara C, et al. (2013) A combined natural supplement lowers LDL cholesterol in subjects with moderate untreatedhypercholesterolemia: a randomized placebo-controlled trial. Int J Food Sci Nutr 64: 882-889.
18. Barrat E, Zaïr Y, Sirvent P, Chauveau P, Maudet C, et al. (2012) Effect on LDL-cholesterol of a large dose of a dietary supplement with plant extracts in subjects with untreatedmoderate hypercholesterolaemia: a randomised, double-blind, placebo-controlled study. Eur J Nutr 52: 1843-1852.
19. Lee IT, Lee WJ, Tsai CM, Su IJ, Yen HT, et al. (2012) Combined extractives of red yeast rice, bitter gourd, chlorella, soy protein, and licorice improve total cholesterol, low-density lipoprotein cholesterol, and triglyceride in subjects with metabolic syndrome. Nutr Res 32: 85-92.
20. Karl M, Rubenstein M, Rudnick C, Brejda J (2012) A multicenter study of nutraceutical drinks for cholesterol (evaluating effectiveness and tolerability). J Clin Lipidol 6: 150-158.
21. Higashikawa F, Noda M, Awaya T, Ushijima M, Sugiyama M (2012) Reduction of serum lipids by the intake of the extract of garlic fermented with Monascus pilosus: a randomized,double-blind, placebo-controlled clinical trial. Clin Nutr 31: 261-266.
22. Marazzi G, Cacciotti L, Pelliccia F, Iaia L, Volterrani M, et al. (2011) Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemicpatients. Adv Ther 28: 1105-1113.
23. Bogsrud MP, Ose L, Langslet G, Ottestad I, Strøm EC, et al. (2010) HypoCol (red yeast rice) lowers plasma cholesterol - a randomized placebo controlled study. Scand Cardiovasc J 44: 197-200.
24. Affuso F, Ruvolo A, Micillo F, Saccà L, Fazio S (2010) Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelialfunction randomized, double-blind, placebo-controlled study. Nutr Metab Cardiovasc Dis 20: 656-661.
25. Yang NC, Chou CW, Chen CY, Hwang KL, Yang YC (2009) Combined nattokinase with red yeast rice but not nattokinase alone has potent effects on blood lipids in humansubjects with hyperlipidemia. Asia Pac J Clin Nutr 18: 310-317.
26. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, et al. (2009) Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial.Ann Intern Med 150: 830-839, W147-149.
27. Huang CF, Li TC, Lin CC, Liu CS, Shih HC, et al. (2007) Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients. Eur J Cardiovasc Prev Rehabil 14: 438-440.
28. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, et al. (1999) Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 69: 231-236. (Pubitemid 29065544)
29. Sathasivam S (2012) Statin induced myotoxicity. Eur J Intern Med 23: 317-324.
30. Tayal U, Carroll R (2013) Should anyone still be taking simvastatin 80 mg? BMJ Case Rep:2013.
31. Arora R, Liebo M, Maldonado F (2006) Statin-induced myopathy: the two faces of Janus. J Cardiovasc Pharmacol Ther 11: 105-112. (Pubitemid 44449099)
32. Becker DJ, Gordon RY, Morris PB, Yorko J, Gordon YJ, et al. (2008) Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin Proc 83: 758-764. (Pubitemid 351948689)
33. Halbert SC, French B, Gordon RY, Farrar JT, Schmitz K, et al. (2010) Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previousstatin intolerance. Am J Cardiol 105: 198-204.
34. Cicero AF, Brancaleoni M, Laghi L, Donati F, Mino M (2005) Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. Complement Ther Med 13: 273-278. (Pubitemid 43032955)
35. Lu JH, Bonovich K, Colfer H, Davidson M, Dujovne CA, et al. (2013) Clinical study on cholesterol-lowering effect of RYR Cholestin among Americans with moderate hy-percholesterolemia. Shanghai Journal of Preventive Medicine 25: 501-506.
36. Childress L, Gay A, Zargar A, Ito MK (2013) Review of red yeast rice content and current Food and Drug Administration oversight. J Clin Lipidol 7: 117-122.
37. Chen CH1, Yang JC, Uang TD, Lin CJ, (2013) Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products. Int J Pharm 444: 18-24.
38. Gordon RY, Cooperman T, Obermeyer W, Becker DJ (2010) Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med 170: 1722-1727.
39. Gheith O, Sheashaa H, Abdelsalam M, Shoeir Z, Sobh M (2008) Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidemia. Clin Exp Nephrol 12: 189-194.
40. Guardamagna O, Abello F, Baracco V, Stasiowska B, Martino F (2011) The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract andpolicosanols. Nutr Metab Cardiovasc Dis 21: 424-429.